Fucase Tamara M, Sciani Juliana M, Cavalcante Ingrid, Viala Vincent L, Chagas Bruno B, Pimenta Daniel C, Spencer Patrick J
Biotechnology Center, Nuclear and Energy Research Institute (IPEN), Av. Lineu Prestes, 2242, São Paulo, SP CEP 05508-000 Brazil.
Laboratory of Biochemistry and Biophysics, Butantan Institute, Av. Vital Brasil, 1500, São Paulo, SP CEP 05503-900 Brazil.
J Venom Anim Toxins Incl Trop Dis. 2017 Jun 26;23:33. doi: 10.1186/s40409-017-0124-9. eCollection 2017.
Venoms represent a still underexplored reservoir of bioactive components that might mitigate or cure diseases in conditions in which conventional therapy is ineffective. The bradykinin-potentiating peptides (BPPs) comprise a class of angiotensin-I converting enzyme (ACE) inhibitors. The BPPs usually consist of oligopeptides with 5 to 13 residues with a high number of proline residues and the tripeptide Ile-Pro-Pro (IPP-tripeptide) in the C-terminus region and have a conserved N-terminal pyroglutamate residue. As a whole, the action of the BPPs on prey and snakebite victims results in the decrease of the blood pressure. The aim of this work was to isolate and characterize novel BPPs from the venom of .
The crude venom of was fractionated by size exclusion chromatography and the peptide fraction (<7 kDa) was separated by reverse phase chromatography (RP-HPLC) and analyzed by ESI-IT-TOF-MS/MS. One new BPP was identified, synthetized and assayed for ACE inhibition and, in vivo, for edema potentiation.
Typical BPP signatures were identified in three RP-HPLC fractions. CID fragmentation presented the usual y-ion of the terminal P-P fragment as a predominant signal at m/z 213.1. peptide sequencing identified one -like BPP and one new BPP sequence. The new BPP was synthesized and showed poor inhibition over ACE, but displayed significant bradykinin-induced edema potentiation.
So far, few BPPs are described in Viperinae, and based on the sequenced peptides, two non-canonical sequences were detected. The possible clinical role of this new peptides remains unclear.
毒液仍是一个尚未充分探索的生物活性成分库,在传统疗法无效的情况下,这些成分可能减轻或治愈疾病。缓激肽增强肽(BPPs)是一类血管紧张素-I转换酶(ACE)抑制剂。BPPs通常由5至13个残基的寡肽组成,脯氨酸残基数量较多,C末端区域有三肽异亮氨酸-脯氨酸-脯氨酸(IPP-三肽),且N末端有一个保守的焦谷氨酸残基。总体而言,BPPs对猎物和蛇咬伤受害者的作用会导致血压下降。这项工作旨在从 毒液中分离和鉴定新型BPPs。
通过尺寸排阻色谱法对 粗毒液进行分级分离,肽级分(<7 kDa)通过反相色谱法(RP-HPLC)分离,并通过电喷雾离子阱飞行时间串联质谱(ESI-IT-TOF-MS/MS)进行分析。鉴定出一种新的BPP,进行合成,并检测其对ACE的抑制作用以及在体内对水肿增强作用的影响。
在三个RP-HPLC级分中鉴定出典型的BPP特征。碰撞诱导解离(CID)碎裂显示,末端P-P片段的常见y离子是m/z 213.1处占主导的信号。 肽测序鉴定出一种类似 的BPP和一个新的BPP序列。合成的新BPP对ACE的抑制作用较弱,但对缓激肽诱导的水肿有显著增强作用。
到目前为止,蝰蛇亚科中描述的BPPs很少,基于测序的肽段,检测到两个非典型序列。这种新肽的潜在临床作用仍不清楚。